

Response and Amendment  
Docket No. 2301-M

Immunex Corporation

### Amendments to the Claims

Applicants respectfully request that the following amendments to the claims be entered and made of record. The amendments are made solely to more particularly recite the claimed subject matter and to expedite prosecution, and are made without prejudice or disclaimer. Applicants reserve the right to pursue withdrawn, cancelled, or amended subject matter in one or more timely filed divisional, continuation, or continuation-in-part applications.

The amendments do not add new matter and are fully supported by the application as originally filed, for example, by Example 13 and by the originally filed claims.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn) A method of inhibiting binding of interleukin-4 (IL-4) to an IL-4 Receptor (IL-4R), said method comprising contacting an IL-4R with an antibody to IL-4R, wherein said antibody inhibits binding of IL-4 to the IL-4R,  
wherein the antibody is reactive with an IL-4R selected from the group consisting of:
  - a) a human IL-4R comprising amino acids 1 to 800 of Figures 4A-4C;
  - b) a soluble human IL-4R comprising amino acids 1 to 207 of Figure 4A;
  - c) a murine IL-4R comprising amino acids 1 to 785 of Figures 2A-2C; and
  - d) a soluble murine IL-4R comprising amino acids 1 to 208 of Figure 2A.
2. (Withdrawn) A method of claim 1, wherein the antibody is a monoclonal antibody.
3. (Withdrawn) A method of claim 1, wherein the antibody is reactive with a soluble human IL-4R, wherein the amino acid sequence of said soluble human IL-4R consists of amino acids 1 to 207 of Figure 4A.
4. (Withdrawn) A method of claim 3, wherein the antibody is a monoclonal antibody.
5. (Withdrawn) A method of claim 1, wherein the antibody inhibits binding of IL-4 to IL-4R on a cell.
6. (Withdrawn) A method of claim 2, wherein the monoclonal antibody inhibits binding of IL-4 to IL-4R on a cell.
7. (Withdrawn) A method of claim 3, wherein the antibody inhibits binding of IL-4 to IL-4R on a cell.

Response and Amendment  
Docket No. 2301-M

Immunex Corporation

8. (Withdrawn) A method of claim 4, wherein the monoclonal antibody inhibits binding of IL-4 to IL-4R on a cell.

9. (Currently Amended) An isolated antibody that is immunoreactive with a mammalian IL-4 receptor (IL-4R) selected from the group consisting of a murine IL-4R protein consisting of amino acids 1 to 785 of Figures 2A-2C and a human IL-4R protein consisting of amino acids 1 to 800 of Figures 4A-4C.